Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.

PubWeight™: 1.07‹?› | Rank: Top 10%

🔗 View Article (PMC 2787394)

Published in Mayo Clin Proc on December 01, 2009

Authors

Thomas P Moyer1, Dennis J O'Kane, Linnea M Baudhuin, Carmen L Wiley, Alexandre Fortini, Pamela K Fisher, Denise M Dupras, Rajeev Chaudhry, Prabin Thapa, Alan R Zinsmeister, John A Heit

Author Affiliations

1: Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.

Articles citing this

Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Med Genet (2011) 0.90

Racial and Ethnic Disparities in Research Studies: The Challenge of Creating More Diverse Cohorts. Environ Health Perspect (2015) 0.87

Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol (2011) 0.83

Warfarin pharmacogenomics in children. Pediatr Blood Cancer (2013) 0.82

Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost (2012) 0.81

Warfarin genotyping using three different platforms. Am J Transl Res (2010) 0.80

Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting. Am J Med (2016) 0.78

Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin. Chest (2015) 0.78

Emerging clinical applications in cardiovascular pharmacogenomics. Wiley Interdiscip Rev Syst Biol Med (2010) 0.77

Impact of genetic polymorphisms on clinical response to antithrombotics. Pharmgenomics Pers Med (2010) 0.77

Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects? EPMA J (2012) 0.76

Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support. ASAIO J (2015) 0.75

Enzyme Polymorphism in Warfarin Dose Management After Pediatric Cardiac Surgery. Res Cardiovasc Med (2015) 0.75

Genotyping three SNPs affecting warfarin drug response by isothermal real-time HDA assays. Clin Chim Acta (2010) 0.75

CYP2C9 Mutation Affecting the Individual Variability of Warfarin Dose Requirement. Ann Rehabil Med (2012) 0.75

Articles cited by this

Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 7.39

Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13

Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet (1996) 6.58

National surveillance of emergency department visits for outpatient adverse drug events. JAMA (2006) 6.24

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation (2007) 5.99

Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48

Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med (2007) 5.29

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26

Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med (1995) 5.16

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood (2005) 4.91

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood (2004) 4.70

Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med (1993) 4.66

Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med (1999) 4.54

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54

Identification of the gene for vitamin K epoxide reductase. Nature (2004) 4.52

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 4.32

CYP4F2 genetic variant alters required warfarin dose. Blood (2008) 4.23

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01

Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J (2005) 3.75

Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ (2003) 3.73

Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med (2000) 3.60

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther (2007) 3.60

Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest (2006) 3.54

Association of warfarin dose with genes involved in its action and metabolism. Hum Genet (2006) 3.27

Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke (2008) 3.14

Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet (1996) 3.03

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet (2005) 2.97

The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) 2.79

Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med (1993) 2.70

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost (2004) 2.64

Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc (1995) 2.55

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther (2007) 2.54

Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J (2006) 2.40

Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost (2005) 2.25

Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood (2008) 2.18

The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology (2007) 2.13

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther (2002) 2.08

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med (2005) 2.06

Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med (2008) 2.05

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res (2005) 2.05

Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther (2007) 2.01

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood (2005) 1.95

A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood (2006) 1.94

Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J (2007) 1.78

Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res (2006) 1.78

Interindividual variability in sensitivity to warfarin--Nature or nurture? Clin Pharmacol Ther (2001) 1.77

Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood (2000) 1.73

The safety of warfarin therapy in the nursing home setting. Am J Med (2007) 1.72

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics (2005) 1.72

Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost (2000) 1.67

Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost (1983) 1.62

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J (2004) 1.51

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med (2008) 1.50

Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther (2008) 1.40

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther (2004) 1.40

Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. Br J Haematol (2006) 1.34

Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Pharmacogenomics (2007) 1.34

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther (2004) 1.31

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis (2002) 1.27

VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther (2006) 1.22

Long-term anticoagulant therapy in patients with coronary artery disease. Eur Heart J (2006) 1.11

Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics (2007) 1.05

Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scand J Prim Health Care (2007) 1.00

Comparison of the native prothrombin antigen and the prothrombin time for monitoring oral anticoagulant therapy. Blood (1984) 0.84

The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med (1994) 0.81

Warfarin: an inconvenient truth. Stroke (2008) 0.79

An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation. Curr Med Res Opin (2007) 0.77

Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis. Circulation (1993) 0.76

Oral anticoagulation in older patients with vascular or cardiovascular diseases. Aged over 70 years: same risk? Same benefit? Int Angiol (2003) 0.76

Articles by these authors

Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98

Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79

Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07

Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 11.84

Internet-based learning in the health professions: a meta-analysis. JAMA (2008) 8.74

Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55

Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24

Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13

A randomized controlled trial of telemonitoring in older adults with multiple health issues to prevent hospitalizations and emergency department visits. Arch Intern Med (2012) 5.00

Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med (2010) 4.77

Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol (2005) 4.39

Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.30

The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol (2011) 3.92

Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med (2003) 3.85

Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83

Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73

Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet (2012) 3.68

Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost (2007) 3.67

Instructional design variations in internet-based learning for health professions education: a systematic review and meta-analysis. Acad Med (2010) 3.56

A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology (2013) 3.56

Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50

The Gene, Environment Association Studies consortium (GENEVA): maximizing the knowledge obtained from GWAS by collaboration across studies of multiple conditions. Genet Epidemiol (2010) 3.48

The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol (2013) 3.11

Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87

The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology (2002) 2.78

Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer (2014) 2.77

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (2009) 2.75

Prevalence and burden of fecal incontinence: a population-based study in women. Gastroenterology (2005) 2.64

Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55

General medicine vs subspecialty career plans among internal medicine residents. JAMA (2012) 2.50

Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol (2003) 2.47

Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.44

A practical guide to developing effective web-based learning. J Gen Intern Med (2004) 2.42

Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol (2012) 2.41

What do we mean by web-based learning? A systematic review of the variability of interventions. Med Educ (2010) 2.38

MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology (2004) 2.35

Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology (2003) 2.35

Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology (2007) 2.30

Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc (2008) 2.30

A study of candidate genotypes associated with dyspepsia in a U.S. community. Am J Gastroenterol (2006) 2.30

Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology (2007) 2.14

Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol (2012) 2.13

Mucosal atrophy in celiac disease: extent of involvement, correlation with clinical presentation, and response to treatment. Clin Gastroenterol Hepatol (2007) 2.07

Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol (2007) 2.06

The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer? J Urol (2013) 1.99

An evaluation of internal medicine residency continuity clinic redesign to a 50/50 outpatient-inpatient model. J Gen Intern Med (2013) 1.99

The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut (2006) 1.97

Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc (2008) 1.97

Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2006) 1.94

Phenotypic identification and classification of functional defecatory disorders using high-resolution anorectal manometry. Gastroenterology (2012) 1.93

Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2008) 1.93

Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes (2013) 1.90

Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol (2009) 1.88

Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology (2008) 1.87

Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol (2009) 1.87

Age-related changes in the pancreas identified by EUS: a prospective evaluation. Gastrointest Endosc (2005) 1.86

Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol (2004) 1.86

Celiac disease serology in irritable bowel syndrome and dyspepsia: a population-based case-control study. Mayo Clin Proc (2004) 1.85

Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol (2005) 1.84

Web-based learning in residents' continuity clinics: a randomized, controlled trial. Acad Med (2005) 1.82

Obstetric trauma, pelvic floor injury and fecal incontinence: a population-based case-control study. Am J Gastroenterol (2012) 1.82

Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology (2002) 1.80

Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol (2012) 1.80

Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer (2012) 1.78

Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab (2003) 1.77

The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology (2008) 1.77

Prevention of venous thromboembolism. Chest (2005) 1.76

A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol (2004) 1.75

Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol (2012) 1.75

Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol (2008) 1.70

Effect of exercise treadmill testing and stress imaging on the triage of patients with chest pain: CHEER substudy. Mayo Clin Proc (2005) 1.69

Increasing incidence of celiac disease in a North American population. Am J Gastroenterol (2013) 1.69

A prospective, randomized, double-blind, placebo-controlled trial of endoscopic steroid injection therapy for recalcitrant esophageal peptic strictures. Am J Gastroenterol (2005) 1.64

Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am J Gastroenterol (2007) 1.63

Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels. Mayo Clin Proc (2011) 1.62

Use of an electronic administrative database to identify older community dwelling adults at high-risk for hospitalization or emergency department visits: the elders risk assessment index. BMC Health Serv Res (2010) 1.61

Methodology for isolation, identification and characterization of microvesicles in peripheral blood. J Immunol Methods (2011) 1.58

UGT1A1 genetic analysis as a diagnostic aid for individuals with unconjugated hyperbilirubinemia. J Pediatr (2013) 1.57

Incidence of pelvic floor repair after hysterectomy: A population-based cohort study. Am J Obstet Gynecol (2007) 1.56

Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med (2010) 1.55

Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology (2010) 1.54

Continuous 12-lead electrocardiographic monitoring in an emergency department chest pain unit: an assessment of potential clinical effect. Ann Emerg Med (2003) 1.54

Use of a clinical decision support system to increase osteoporosis screening. J Eval Clin Pract (2010) 1.54

Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology (2010) 1.53

Effect of alginate on satiation, appetite, gastric function, and selected gut satiety hormones in overweight and obesity. Obesity (Silver Spring) (2009) 1.52

Symptoms and quality of life in community women with fecal incontinence. Clin Gastroenterol Hepatol (2006) 1.52

Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology (2006) 1.51

Factors that predict relief from upper abdominal pain after cholecystectomy. Clin Gastroenterol Hepatol (2011) 1.50

Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol (2012) 1.47

Evaluation of a screening tool for bleeding disorders in a US multisite cohort of women with menorrhagia. Am J Obstet Gynecol (2011) 1.47

A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome. Am J Gastroenterol (2009) 1.47

Effect of prior radiotherapy and ablative therapy on surgical outcomes for the treatment of rectourethral fistulas. J Urol (2013) 1.46

Gastric sensory and motor dysfunction in adolescents with functional dyspepsia. J Pediatr (2005) 1.46

Psychosocial distress and somatic symptoms in community subjects with irritable bowel syndrome: a psychological component is the rule. Am J Gastroenterol (2009) 1.46

Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol (2008) 1.44